Eli Lilly may drop inhaled insulin plan

Mar 10, 2008

Eli Lilly and Co. has pulled the plug on a collaboration with a Massachusetts company to develop inhaled insulin for diabetics.

Alkermes Inc. said it received a letter Friday from Lilly terminating the development and license agreement for AIR Inhaled Insulin. The announcement was made shortly after Alkermes released a statement that Lilly was evaluating its business case for the drug.

AIR Insulin is being evaluated in a broad phase-3 clinical trial program with patients with type 1 and type 2 diabetes. Alkermes said it was not aware of any safety, efficacy or manufacturing issues that would lead to the termination of the agreement.

Copyright 2008 by United Press International

Explore further: FDA warns of compounded drug recall by Texas firm

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Journal raises concern about blood-thinning drug

12 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

User comments : 0